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Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) is a poorly characterized condition. We aimed
to phenotype patients with HFpEF using multiparametric stress cardiovascular magnetic resonance imaging (CMR)
and to assess the relationship to clinical outcomes.
Methods: One hundred and fifty four patients (51% male, mean age 72 ± 10 years) with a diagnosis of HFpEF
underwent transthoracic echocardiography and CMR during a single study visit. The CMR protocol comprised
cine, stress/rest perfusion and late gadolinium enhancement imaging on a 3T scanner. Follow-up outcome
data (death and heart failure hospitalization) were captured after a minimum of 6 months.
Results: CMR detected previously undiagnosed pathology in 42 patients (27%), who had similar baseline characteristics
to those without a new diagnosis. These diagnoses consisted of: coronary artery disease (n = 20, including 14 with ‘silent’
infarction), microvascular dysfunction (n = 11), probable or definite hypertrophic cardiomyopathy (n = 10) and constrictive
pericarditis (n = 5). Four patients had dual pathology. During follow-up (median 623 days), patients with a new CMR
diagnosis were at higher risk of adverse outcome for the composite endpoint (log rank test: p = 0.047). In multivariate Cox
proportional hazards analysis, a new CMR diagnosis was the strongest independent predictor of adverse outcome (hazard
ratio: 1.92; 95% CI: 1.07 to 3.45; p = 0.03).
Conclusions: CMR diagnosed new significant pathology in 27% of patients with HFpEF. These patients were at increased
risk of death and heart failure hospitalization.
Trial registration: ClinicalTrials.gov Identifier: NCT03050593. Retrospectively registered; Date of registration: February 06,
2017.
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Background
Heart failure with preserved ejection fraction (HFpEF)
presents with marked clinical heterogeneity and ac-
counts for approximately half of all heart failure (HF)
cases. It is projected to be the predominant phenotype
in the near future [1, 2]. While treatments have im-
proved outcomes in heart failure with reduced ejection
fraction (HFrEF), similar therapies have not been shown
to improve outcome in HFpEF and there remain no spe-
cific, evidence-based treatments [3]. Furthermore, a wide
range of pathologies such as silent myocardial infarction
(MI) and ischaemia due to coronary artery disease
(CAD), hypertrophic cardiomyopathy (HCM) and con-
strictive pericarditis may masquerade as HFpEF [4–6].
These ‘phenocopies’ may share many features of HFpEF
such as preserved ejection fraction (EF), left ventricular
hypertrophy (LVH), diastolic dysfunction, atrial dilata-
tion and elevated natriuretic peptides. Hence, focus has
shifted to studying ‘purer’ forms of HFpEF by excluding
such conditions from contemporary clinical trials [7].
Transthoracic echocardiography (TTE) remains the pri-
mary diagnostic tool for HFpEF [8] and the gatekeeper for
entry into clinical trials of this entity [3, 7]. However,
cardiovascular magnetic resonance imaging (CMR) is the
recognized gold standard for assessment of the majority of
parameters that make up the latest HFpEF guidelines [8–
11]. The superior diagnostic capabilities of CMR across the
spectrum of aforementioned ‘phenocopies’ is also well
established [5, 12–14]. However, no reports in the literature
detail the systematic use of CMR in patients with suspected
HFpEF. We aimed to establish the proportion of new
clinical diagnoses in HFpEF patients identified with CMR,
and to assess their impact upon clinical outcome.
Methods
Study population
Patients were recruited as part of an observational cohort
study conducted at a single tertiary cardiac centre. The
inclusion criteria were: clinical or radiographic evidence of
HF, EF > 50% on transthoracic echocardiography (TTE)
and age ≥ 18 years. The exclusion criteria were: MI in the
preceding 6 months, suspected or confirmed cardiomyop-
athy or constrictive pericarditis, non-cardiovascular life
expectancy <6 months, severe native valve disease, severe
chronic obstructive pulmonary disease (or forced expira-
tory volume [FEV1] < 30% predicted or forced vital cap-
acity [FVC] <50% predicted) and estimated glomerular
filtration rate (eGFR) < 30 ml/min per 1.73m2. The study
was approved by the National Research Ethics Service. All
subjects provided written informed consent prior to
participation.
Potentially eligible patients were invited to participate
following screening of the hospital database, outpatient
clinics and wards. All enrolled patients underwent
comprehensive clinical assessment (including patient
reporting of angina symptoms and previous MI or revas-
cularization), venepuncture, 12-lead electrocardiography
(ECG) and TTE followed by CMR (provided no contrain-
dications) during the same visit. The clinical reports of all
scans were disseminated to the responsible physician(s) to
inform patient management.
Blood samples
Blood was sampled for B-type natriuretic peptide (BNP)
immunoassay (Siemens, Erlangen, Germany) and other
biochemical markers (sodium, urea and creatinine).
Estimated GFR was calculated from the Modification of
Diet in Renal Disease formula.
ECG
The 12-lead ECGs performed were assessed (by PK and
AMM) for the presence of pathological Q waves as surro-
gates of transmural MI [15].
Imaging
Clinical reports were generated for TTE and CMR scans
with knowledge of patient demographics and past medical
history (e.g. history of hypertension). All subsequent
quantitative and qualitative analyses used to generate the
reports were performed independently with readers
blinded to data from the other scan. Image quality was
graded as: 0 = non-interpretable; 1 = poor; 2 = fair; 3 =
good.
TTE
TTE studies were performed and reported by two accre-
dited sonographers (AMM, JM). Images were acquired and
reported as per American Society of Echocardiography
guidelines using an iE 33 system with S5–1 transducer
(Philips Medical Systems, Best, The Netherlands) [16]. Left
ventricular (LV) EF for study inclusion was calculated
using the biplane method or estimated visually in cases of
poor endocardial border definition. For borderline cases,
final consensus required review by a third observer (PK).
Any regional wall motion abnormalities (RWMA) were
reported.
CMR
CMR scans were performed on a 3T scanner (Siemens
Skyra Erlangen, Germany) with an 18-channel cardiac coil.
The protocol was previously reported by our group [17].
Cine imaging was performed in three long axes and a short
axis cine stack was performed in the interval between
stress and rest perfusion acquisitions. For pharmacological
stress, 140–210 mcg/kg/min adenosine (depending on
haemodynamic and symptomatic response) was infused
for at least 3 min. Stress and rest perfusion images at the
basal, mid-ventricular and apical levels were acquired after
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injection of 0.04 mmol/kg of contrast (Gadovist, Bayer
Healthcare, Berlin, Germany). Following rest perfusion, a
‘top-up’ bolus of 0.07 mmol/kg was given to make a total
contrast dose of 0.15 mmol/kg. Late gadolinium enhance-
ment imaging (LGE) was performed 10–15 min after the
final injection of contrast.
CMR analyses and reporting were undertaken with
cases randomly split between two experienced imaging
cardiologists (GPM, ASHC). LV EF and volumes, wall
thickness and perfusion were assessed using commercially
available software (Argus, Siemens Healthineers, Erlangen,
Germany). LV contours were drawn manually (excluding
papillary muscles) to derive end-diastolic and end-systolic
volumes and LVEF from the short-axis cine stack as re-
ported by our group previously with excellent intra-
observer and inter-observer variability [18]. Volumetric
data were indexed to body surface area.
Definitions of ‘new diagnoses’ from CMR
MI was defined as high signal intensity area(s) on LGE
involving at least the sub-endocardium in a coronary ar-
tery distribution and the segmental extent and transmur-
ality were described. For ischaemia evaluation, in
conjunction with LGE images, stress and rest perfusion
images were semi-quantitatively assessed for reversible
perfusion defects. The defects were categorized into
ischaemia likely to be due to epicardial CAD or micro-
vascular dysfunction [19]. Ischaemia was defined by the
identification of inducible perfusion defects as per
published Society for Cardiovascular Magnetic Reson-
ance guidance [19]. Circumferential, sub-endocardial
perfusion defects seen at least on one ventricular level
or crossing coronary territories were reported as sug-
gestive of microvascular dysfunction, albeit with the cav-
eat that significant CAD could not be reliably excluded.
Constrictive pericarditis (e.g. diastolic septal bounce,
pericardial effusion, thickening and hyperenhancement
on LGE) and HCM were diagnosed based on established
CMR parameters [5, 12, 14, 20]. A diagnosis of HCM
was considered in all patients with LV wall thickness of
≥15 mm [12]. In such cases, the degree and pattern of
LVH and medical history (including hypertension, blood
pressure control, anti-hypertensive medications) were
considered to gauge whether wall thickness was propor-
tionate or disproportionate. A characteristic spade-like
configuration of the LV cavity and apical:basal wall thick-
ness ratio ≥ 1.3 was used to diagnose apical HCM [14].
The overall likelihood of HCM was categorized as defin-
ite or probable.
Follow-up and endpoints
Patients were followed up for a minimum of 6 months
post-study entry. The primary endpoint was the combin-
ation of hospitalization for HF (defined as a hospital
admission for which HF was the primary reason and which
required diuretic, inotropic or intravenous nitrate therapy)
or all-cause mortality. Hospital databases and patient
records were sourced to obtain outcome data.
Statistical analysis
Statistical analyses were performed using SPSS (version 22,
International Business Machines, Inc., Armonk, New York,
USA). Probability (p) values <0.05 were considered statisti-
cally significant. Normality was assessed using the Shapiro-
Wilk test, histograms and Q-Q plots. Normally distributed
data are expressed as mean ± SD. Non-parametric data are
expressed as median (25–75% interquartile range [IQR]).
Categorical data are expressed as absolute numbers or
percentages. Comparisons of means of 2 groups were
performed using the independent samples t test. The chi-
square test was used to compare categorical data. Cohen’s
Kappa (Κ) was used to test for agreements of similarities in
image grading between CMR and TTE (p > 0.05 was con-
sidered significant). Cox proportional hazard and multiple
regression analyses were performed to determine which
variables were related significantly to the composite end-
point of death and/or hospitalization with HF. BNP levels
were log10 transformed and hazard ratios for subsequent
analysis refer to 1 standard deviation (SD) increment of the
transformed BNP. Only variables with a univariate p value
<0.10 were entered into subsequent multivariate analysis.
Kaplan-Meier survival curves were used to demonstrate cu-
mulative event-free rates in patients stratified into 2 CMR
groups (‘no new diagnoses’ versus ‘new diagnoses’) and a
log rank test was used to test for statistical significance.
Results
A summary of the study overview, patients excluded and
results are presented in Fig. 1. One hundred and ninety
six patients attended for screening. Severe lung disease
was the most common reason for exclusion. One hundred
and eighty patients met the initial study inclusion criteria.
The majority of patients who did not undergo subsequent
CMR evaluation were either claustrophobic or had
pacemakers.
A total of 154 patients underwent CMR, of whom 5 did
not undergo stress perfusion imaging. Baseline characteris-
tics of the CMR population stratified by the presence or
absence of new CMR diagnoses, are summarized in
Table 1. Patients with and without new diagnoses on CMR
had similar baseline characteristics, including LV volumes
and LVEF. The cohort had a wide age range (37–97 years)
with the majority of patients over 65 years. Nearly one-
third were in NYHA class III or IV. There was a high
prevalence of obesity and hypertension and nearly half the
patients had a history of atrial fibrillation and a similar
proportion of diabetes. Approximately a fifth had chronic
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lung disease. The proportion of patients with CAD at
baseline was 21%, including 15 patients with known MI.
Imaging
Overall, image quality was better for CMR compared to
TTE (median grade: 3 vs 2 respectively). In those with a
new diagnosis on CMR, this difference was also main-
tained and statistically significant (kappa statistic
[−0.021], p = 0.72).
‘New diagnoses’ from CMR
CMR identified previously unknown diagnoses in 42
patients (27%). The following new pathologies (see Fig. 1)
were noted: epicardial CAD based on MI or ischaemia (n
= 20), microvascular dysfunction (n = 11), HCM (n = 10)
and constrictive pericarditis (n = 5). Three patients with
HCM had co-existent CAD (2 with new MI and 1 with
ischaemia). One patient with constrictive pericarditis also
had concurrent MI. Examples are shown in Fig. 2.
CAD
Fourteen patients had LGE indicating ‘silent’ MI (affecting
37 segments). Of these, 3 patients had known CAD at
baseline but no prior known MI or pathological Q waves
on ECG. On segmental analysis (see Fig. 3), infarcts were
typically small, in a territory not subtended by the left an-
terior descending coronary artery (95%) and of <50%
transmurality (68%). Corresponding RWMAs on TTE
were only reported in 38%. As expected, the ability to
diagnose MI by regional wall motion abnormality
(RWMA) detectable by TTE worsened with diminishing
transmurality of MI (0–50% [24%] versus 51–100%
[67%]). On review of the corresponding ECGs, only one
case fulfilled the Q wave criterion for MI [15].
There were 31 patients with reversible perfusion defects
and in 11 of these, the pattern suggested microvascular
dysfunction. In the remaining 20 patients with ischaemia in
an epicardial CAD pattern, 13 had no prior known CAD. Of
these 13 patients, CMR detected a new diagnosis of MI in 4
patients. Accounting for these, CAD was newly diagnosed in
20 patients (new MI in 11 and new ischaemia in 9).
HCM
Findings consistent with HCM (definite: n = 4; prob-
able: n = 6) were reported in CMR studies of 10 pa-
tients. Individual patient characteristics are shown in
Table 2. The main CMR phenotypic patterns of HCM
were: asymmetrical septal hypertrophy (70%), focal fi-
brosis on LGE (70%) and maximal hypertrophy at the
basal anteroseptum (50%). With TTE, measured wall
thickness was significantly lower (mean difference 2.3 ±
2.2 mm, p < 0.05), compared to CMR. TTE criteria for
diagnosis of HCM were reported in only 50% of cases
Fig. 1 Study overview. *Of the 20 patients with newly diagnosed coronary artery disease (CAD), 4 patients had concomitant hypertrophic
cardiomyopathy (HCM)
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of new CMR diagnosis of HCM. The pattern of LVH on
TTE was primarily concentric.
Constrictive pericarditis
Constrictive pericarditis was identified in 5 patients,
with at least 3 out of the 4 main diagnostic parameters
for CMR present in all cases (see Table 3). Whilst peri-
cardial thickening on CMR was universally reported in
patients with constrictive pericarditis, this finding was
not identified in any of the TTE reports. Furthermore,
in 3 out of 4 patients, TTE failed to identify septal
bounce that was observed with CMR.
Table 1 Baseline characteristics of the patients who underwent CMR
All No new diagnoses
group (n = 112)
New diagnoses
group (n = 42)
p value
Demographics
Age, years 72 ± 10 73 ± 9 72 ± 12 0.61
Male 78 (50.6) 54 (48.2) 24 (57.1) 0.32
Clinical findings
Atrial fibrillation 72 (46.8) 50 (44.6) 24 (52.4) 0.42
Heart rate (bpm) 70 ± 14 70 ± 14 72 ± 16 0.57
Systolic blood pressure (mmHg) 143 ± 25 144 ± 25 146 ± 26 0.61
Diastolic blood pressure (mmHg) 74 ± 12 74 ± 12 74 ± 13 0.99
Body mass index (kg/m2) 34 ± 7 34 ± 7 33 ± 9 0.66
NYHA
I/II 106 (68.8) 77 (68.8) 29 (69.0) 0.97
III/IV 48 (31.2) 35 (31.3) 13 (31.0)
Medical History
Known coronary artery disease 32 (20.8) – – –
Hypertension 139 (90.3) 111 (89.3) 39 (92.9) 0.60
Diabetes 75 (48.7) 54 (48.2) 21 (50.0) 0.88
Chronic obstructive pulmonary
disease or asthma
27 (17.5) 17 (15.2) 10 (23.8) 0.21
Chest radiography
Pulmonary edema 110 (71.4) 79 (70.5) 31 (73.8) 0.69
Medication
Aspirin 54 (35.1) 42 (37.5) 12 (28.6) 0.30
Beta-blocker 99 (64.3) 74 (66.1) 25 (59.5) 0.45
ACEi or ARB 130 (84.4) 97 (86.6) 33 (78.6) 0.22
Statin 97 (63.0) 70 (62.5) 27 (64.3) 0.84
Loop diuretic 125 (81.2) 91 (81.3) 34 (81.0) 0.97
Biochemistry
Sodium (mmol/L) 139 ± 3.4 139 ± 3.6 140 ± 2.6 0.39
Urea (mmol/L) 8.7 ± 3.8 8.8 ± 4.0 8.3 ± 3.5 0.46
eGFR (ml/min per 1.73m2) 66 ± 19 66 ± 19 64 ± 19 0.46
BNP (ng/L, median, IQR) 145 (66–259) 134 ± (57.5–251) 175 ± (111–263) *0.12
CMR
LVEF (%) 57 ± 6 57 ± 6 57 ± 7 0.98
LVEDVI (ml/m2) 74 ± 18 73 ± 17 77 ± 21 0.26
LVESVI (ml/m2) 33 ± 11 32 ± 10 34 ± 13 0.30
Values are mean ± SD or n (%). The p values are for the t-test or chi-square test. ACEi angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor
blocker, BNP B-type natriuretic peptide, CMR cardiovascular magnetic resonance imaging, eGFR estimated glomerular filtration rate, LVEF left ventricular ejection
fraction, LVEDVI left ventricular end-diastolic volume indexed to body surface area, LVESVI left ventricular end-systolic volume indexed to body surface area; * p
value refers to zlog10 transformed BNP
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Clinical outcome
During a median follow-up of 623 days (IQR 455–
753), there were a total of 53 events (19 deaths, 34
hospitalizations with HF). Of these, ‘the new CMR
diagnoses group’ accounted for 20 events (8 deaths,
12 hospitalizations with HF). Event-free rates (Fig. 4)
were significantly lower in the ‘new CMR diagnoses’
group (52.4% vs 70.5%, log rank test: p < 0.05). The
results of univariate and multivariate Cox propor-
tional hazards analysis to predict events are shown in
Table 4. On multivariate analysis, a new CMR diagno-
sis (hazard ratio [HR]: 1.92; 95% confidence interval
Fig. 2 Examples of typical findings in the ‘new diagnoses’ group. CMR images of: a sub-endocardial, inferolateral myocardial infarction of 25–50%
transmurality on LGE; b inferoseptal and inferior perfusion defect consistent with right coronary artery territory ischaemia; c global, concentric
perfusion defect consistent with microvascular dysfunction; d horizontal long axis cine demonstrating asymmetrical septal hypertrophy in HCM; E)
constrictive pericarditis with circumferential pericardial hyperenhancement on LGE; white arrows point towards pathology; LGE = late gadolinium
enhancement imaging
Fig. 3 Characteristics of newly diagnosed myocardial infarction according to coronary arterial distribution and transmurality. LAD = left anterior
descending artery; RCA = right coronary artery; LCX = left circumflex artery; % transmurality of MI is illustrated as 1–25, 26–50, 51–75, 76–100;
RWMA = regional wall motion abnormality
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[CI]: 1.06 to 3.45; p < 0.05), log BNP (HR: 1.44; CI:
1.03 to 2.02; p < 0.05, and urea (HR: 1.10; CI: 1.01 to
1.21; p < 0.05) were predictors of the primary
endpoint.
Discussion
The principal finding in our study is that stress CMR
unmasks potentially clinically relevant undiagnosed cardiac
pathology in a significant proportion of patients (27%) la-
belled as HFpEF after echocardiography. A clinically rele-
vant proportion of our patients was identified as having
hitherto unknown coronary artery disease or microvascular
dysfunction. Moreover, despite being part of the TTE-based
exclusion criteria at study entry, new cases of HCM and
constrictive pericarditis were identified during subsequent
CMR evaluation. Our observations suggest that previous
intervention trials in HFpEF are likely to have included pa-
tients meeting one or more exclusion criteria, thereby pos-
sibly influencing treatment response. These additional
pathologies, when grouped together in our cohort, were as-
sociated with adverse outcomes.
‘New CMR diagnoses’
The reasons for the higher pick-up rate of new clinical
diagnoses with CMR are multiple. Firstly, the overall
image quality for TTE in our study was poor, reflecting
the clinical profile of our challenging population, with a
high prevalence of obesity, lung disease and atrial fibril-
lation [21]. These comorbidities are typical of HFpEF as
reported in the literature [1]. Furthermore, the low feasi-
bility (inadequate endocardial border definition in nearly
one-third) and diagnostic utility of TTE in HF has previ-
ously been reported and is subject to wider limits of
agreement compared with CMR [9, 22]. The ability of
CMR to interrogate any imaging plane and perform in
vivo tissue characterization (e.g. by LGE) makes this the
reference standard for detection of new diagnoses in our
cohort [9–11].
Previous reports quote a wide range for the prevalence
of CAD in HFpEF, comprising primarily data from epi-
demiological studies and registries. Furthermore, the
presence of CAD was variably based on patient report-
ing, use of insensitive and non-specific investigations
(e.g. ECG, exercise treadmill tests), inconsistent diagnos-
tic cut-offs for angiographic disease severity, and did not
incorporate CMR [23]. In this study, CMR increased the
overall proportion of significant CAD (silent MI and/or
ischaemia) from 21% to 34%, equivalent to a relative in-
crease of 63%. These findings (and microvascular dys-
function) might be expected, given the proportion of
elderly, hypertensive and diabetic patients in our cohort
[24]. Furthermore, these greater number of ‘new’ CAD
diagnoses is perhaps unsurprising given that CAD was
not part of our exclusion criteria. We used a practical







Age 1.01 (0.99–1.05) 0.34
Gender 1.48 (0.84–2.60) 0.17
Clinical Findings






0.97 (0.95–1.00) 0.03 0.99 (0.97–1.02) 0.48
NYHA III/IV 1.80 (1.02–3.17) 0.04 1.55 (0.83–2.89) 0.17
Medical history
Hypertension 2.40 (0.58–9.87) 0.23
Diabetes 1.03 (0.59–1.79) 0.91
Biochemistry
Sodium (mmol/L) 0.97 (0.90–1.05) 0.45
Urea (mmol/L) 1.09 (1.02–1.15) 0.01 1.10 (1.01–1.21) 0.04
eGFR (ml/min per 1.73m2) 0.99 (0.97–1.00) 0.07 1.01 (0.99–1.03) 0.37
ZLog BNP (ng/L) 1.47 (1.08–2.01) 0.02 1.44 (1.03–2.02) 0.03
CMR findings
New diagnoses group 1.75 (1.00–3.07) 0.05 1.92 (1.06–3.45) 0.03
Abbreviations are as for Table 1 and HR hazard ratio, CI confidence interval
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Table 3 Characteristics of newly diagnosed hypertrophic cardiomyopathy patients




Maximal wall thickness Hypertrophy pattern SAM LVOTO LGE hyperenhancement Likelihood
of HCMmm region ASH Concentric Mid-wall Insertion point
A 71 + TTE 2 15 Basal inferoseptum – + – – n/a Definite
CMR 2 19 Basal anteroseptum + – – – + +
aB 85 – TTE 3 12 Apical septum – + – – n/a Definite
CMR 3 10 Apical septum – – – – – –
C 79 + TTE 1 15 Basal inferoseptum – + + – n/a Probable
CMR 2 15 Basal anteroseptum + – – – – +
D 37 – TTE 1 17 Basal inferoseptum u/a u/a u/a u/a n/a Definite
CMR 3 22 Basal inferoseptum – + – – + +
E 68 + TTE 2 16 Basal inferoseptum – + – – n/a Definite
CMR 2 21 Basal anteroseptum + – – – + –
F 87 + TTE 2 12 Basal inferoseptum – + + + n/a Probable
CMR 3 15 Basal anteroseptum + – + + + +
G 62 + TTE 2 13 Basal inferoseptum – + + – n/a Probable
CMR 2 15 Basal inferoseptum + – + – – –
H 70 + TTE 1 14 Basal anteroseptum – + – – n/a Probable
CMR 2 15 Mid inferoseptum + – – – + –
I 74 – TTE 1 14 Basal anteroseptum – + – – n/a Probable
CMR 3 17 Basal inferoseptum – + – – – –
J 72 + TTE 1 16 Basal anteroseptum – + – – n/a Probable
CMR 3 18 Basal anteroseptum + – – – + –
Abbreviations: TTE = transthoracic echocardiography; CMR = cardiac magnetic resonance; HTN = hypertension, LGE = late gadolinium enhancement imaging; u/a =
unable to assess; n/a = not applicable; − = absent; + = present
Image grade: 1 = poor; 2 = fair; 3 = good
Diagnostic considerations for hypertrophic cardiomyopathy (HCM): LV wall thickness ≥ 15 mm, asymmetrical septal hypertrophy (ASH – septal: free wall thickness
ratio > 1.3), apical HCM if apical wall thickness > 15 mm or apical:basal wall thickness ratio ≥ 1.3, left ventricular outflow tract obstruction (LVOTO) and systolic
anterior motion of the mitral valve (SAM)
aNote: Patient B was diagnosed with apical HCM (spade-like configuration of the LV cavity and apical: basal wall thickness ratio ≥ 1.3)
Fig. 4 Kaplan Meier analysis for the composite endpoint of death and/or hospitalization with heart failure. Nil
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definition of HFpEF and current clinical guidelines [25]
for HF do not mandate routine investigation for CAD
unless accompanied by anginal symptoms recalcitrant to
medical therapy. Additionally, the higher numbers of ‘si-
lent’ CAD could also be explained by the inability of
some patients to provoke clinical symptoms due to lim-
ited exercise capacity owing to co-morbidities. Con-
versely, exertional breathlessness may represent angina
equivalent. The typical patterns of infarction (small
number of segments and ≤50% transmurality) in our
study are in keeping with overall preservation of LVEF.
In such cases, the diagnostic accuracies of both ECG (Q
wave) and TTE (RWMAs) are low in concordance with
published literature [26].
Diagnosing HCM represents an imaging challenge in
this cohort of patients. The latest HCM diagnostic guide-
lines [12] advocate a morphological description of imaging
in suspected subjects. These guidelines are also more in-
clusive of considering HCM as a diagnosis in any patients
whereby increased LV wall thickness cannot solely be ex-
plained by abnormal loading conditions. CMR features
supportive of HCM in hypertensive patients include a
more asymmetric pattern of LVH and LGE at the inser-
tion points and in segments of maximal LV wall thicken-
ing [27, 28]. Furthermore, LGE is reportedly present in
65% with HCM, similar to our cohort [12].
HCM is characterized by non-specific diverse pat-
terns of hypertrophy with or without left ventricular
outflow tract obstruction or systolic anterior motion
of the mitral valve [12, 14, 29]. In HFpEF, LVH is a
common finding [1] and co-existing conditions such
as ageing, obesity and hypertension are additional con-
founders [30]. Furthermore, hypertensive heart disease
classically presents with concentric hypertrophy and
wall thickness rarely exceeds 15–16 mm [28]. Deci-
phering the pattern of LVH according to mass and
relative wall thickness calculations traditionally used
in TTE is fraught with intrinsic methodological limita-
tions [31]. These factors along with sub-optimal image
quality [29] and the very high prevalence of hyperten-
sion (90%) may explain the underreporting of HCM by
TTE in our cohort. In our study, patients who met
wall thickness criteria for HCM on TTE were not re-
ported as likely HCM most probably due to a predom-
inant concentric pattern of LVH. Whilst TTE
traditionally risks overestimating wall thickness (e.g.
oblique cuts) [12], underestimation has been noted in
a small (12%) proportion, especially if confined to the
inferolateral, anterolateral or apical segments. In con-
trast, the superior endocardial definition afforded by
CMR allows a more precise measurement of LV wall
thickness and hypertrophy [29].
Current TTE diagnostic criteria for constrictive
pericarditis have lower sensitivities compared to CMR
(pericardial thickening: 36% vs 88%, septal bounce:
62% vs 81%) [5, 20]. In our cohort, the majority of
these TTE parameters were not detected, which again
is a likely reflection of poor image quality.
Implications
Our CMR findings reinforce the marked clinical het-
erogeneity in HFpEF [1] and provide alternative ex-
planations for symptoms in a significant minority of
patients. Survival following silent MI is comparable to
known MI [32]. Importantly, diagnosis by CMR en-
ables initiation of effective secondary prevention treat-
ment and guides revascularization, given that most
affected myocardial segments identified in our cohort
were viable [13]. Our data suggest that screening for
significant CAD should be undertaken in patients
with suspected HFpEF. A diagnosis of HCM has im-
plications for both patients and relatives. CMR im-
proves risk stratification and may enable earlier
initiation of therapies such as implantable defibrillator
devices [12]. Constrictive pericarditis is potentially
curable and pericardial enhancement on LGE may
predict treatment response [5].
Implications for current HFpEF clinical trials
Our study has important implications and ramifications
for HFpEF clinical trials and current treatment
Table 4 Imaging characteristics of newly diagnosed constrictive pericarditis patients
Patient Image grade Pericardial thickening Pericardial effusion Septal bounce Septal E’ ≥ 9 cm/s Pericardial
enhancement
TTE CMR TTE CMR TTE CMR TTE CMR TTE CMR
A 2 2 – + + + – – – +
B 2 3 – + – + – + + +
C 1 3 – + – – – + + +
D 1 2 – + – + – + + –
E 1 3 – + + + + + – +
Abbreviations: TTE transthoracic echocardiography, CMR cardiac magnetic resonance; − = absent; + = present
Image grade: 1 = poor; 2 = fair; 3 = good
Kanagala et al. Journal of Cardiovascular Magnetic Resonance  (2018) 20:4 Page 9 of 12
strategies. Variable definitions of HFpEF and phenotypic
heterogeneity displayed in prior studies have previously
been proposed as a key reasons for treatment failure [1,
3]. This has led to a paradigm shift in focus to study
‘purer’ subsets of HFpEF resulting in more detailed
mechanistic studies. Our CMR study findings provide
additional explanations for such poor outcomes whereby
TTE remains the primary entry tool for trial enrolment.
Our data suggests that TTE alone is incapable of rigor-
ously excluding imaging phenocopies of HFpEF prior to
study entry. Such conditions have alternate pathophysio-
logical mechanisms, respond differently to existing ther-
apies and contribute to adverse outcomes. While TTE is
comparatively more extensively available, and therefore
attractive for clinical trial design, access to CMR is rap-
idly increasing. Furthermore, CMR refines the diagnosis
and sub-categorises HFpEF into ‘purer forms’ and alter-
native pathologies, enabling disease-specific tailored
therapies, and provides prognostic data.
The routine use of stress CMR in HFpEF patients
should refine diagnosis and treatment strategies as we
move towards an era of precision medicine. However,
further randomised trials are needed to assess the wider
impact of CMR in terms of clinical outcome, resource
utilization and cost-effectiveness.
Limitations
The definition of HFpEF used in our study was not in
accordance with current European Society of Cardiology
(ESC) guidelines [8]. However, we took a pragmatic
approach to reflect a real world setting. In particular, the
presence of diastolic dysfunction was not a pre-requisite
for study entry since recent contemporary clinical trials
have highlighted normal diastolic function at rest in
approximately a third of such patients [7]. Although all
patients meeting inclusion criteria were invited, 26 out of
180 (14%) did not undergo CMR, which might raise con-
cerns about its applicability to the wider HFpEF popula-
tion. Whilst chronic obstructive pulmonary disease is
quite prevalent in the clinical scenario of HFpEF, we only
excluded patients with severe disease (and likewise severe
valvular disease) to minimise the contribution from alter-
nate causes of HF symptoms. Besides our cohort still com-
prised chronic obstructive pulmonary disease subjects in
nearly one-fifth who underwent CMR. Six patients with
pacemakers did not undergo CMR: at the time the study
was conducted, our centre was not implanting CMR con-
ditional devices. Although all CMR scans were performed
solely at 3 T, we expect the study findings to be similar
with a 1.5 T system.
Discriminating microvascular dysfunction from global
coronary ischaemia can be challenging with CMR and
raises the possibility of under-reporting of CAD.
Furthermore, patients did not have stress echocardiog-
raphy which may have identified more patients with is-
chaemia. In this cohort of patients with multiple risk
factors for LVH, ultimately the imaging diagnosis of
HCM is one of exclusion. However, the most recent ESC
guidelines recommend defining HCM in patients with
LVH ≥ 15 mm not solely explained by loading conditions
[12]. Our CMR reports were generated using a clinical
protocol exclusive of T1 and T2 mapping which were
not routinely used at the time of study conduct. T1
mapping may have unmasked further hypertrophic phe-
notypes [12] such as cardiac amyloid and Anderson-
Fabry’s disease, and T2 mapping may have been helpful
in cases of constrictive pericarditis [5].
While the CMR reports were generated by GPM and
ASHC, clinical endpoints were collated by PK who was
not blind to CMR results. However, the HF hospitalization
events were clearly objectively defined (see methods
section) and assessment of vital status is robust. Some
patients may have had hospitalizations exclusive of our
hospital. However, there should be no systematic bias for
those with or without ‘new’ diagnoses.
Conclusions
In HFpEF, CMR identifies previously undetected path-
ology in a significant proportion of patients. This group
of additional diagnoses is associated with worse out-
comes and is an independent predictor of death and
hospitalization due to HF.
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